reslizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5093 241473-69-8

Description:

MoleculeDescription

Synonyms:

  • reslizumab
  • SCH 55700
  • cinqair
  • SCH-55700
Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Reslizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of reslizumab action in asthma has not been definitively established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
7.10 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 16, 2016 EMA Teva Pharmaceuticals Limited
March 23, 2016 FDA TEVA RESPIRATORY LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Adrenal suppression 50.63 44.35 8 301 864 50603951

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DX08 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Other systemic drugs for obstructive airway diseases
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
FDA MoA N0000191871 Interleukin-5 Antagonists
FDA EPC N0000191872 Interleukin-5 Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Eosinophilic asthma indication 367542003 DOID:9498




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-5 Cytokine ANTIBODY BINDING Kd 10.09 DRUG LABEL DRUG LABEL

External reference:

IDSource
35A26E427H UNII
D08985 KEGG_DRUG
4035617 VANDF
C1869620 UMLSCUI
CHEMBL2107884 ChEMBL_ID
DB06602 DRUGBANK_ID
8106 INN_ID
C515492 MESH_SUPPLEMENTAL_RECORD_UI
8091 IUPHAR_LIGAND_ID
1746889 RXNORM
239672 MMSL
31580 MMSL
d08427 MMSL
717178009 SNOMEDCT_US
781214008 SNOMEDCT_US
016751 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CINQAIR HUMAN PRESCRIPTION DRUG LABEL 1 59310-610 INJECTION, SOLUTION, CONCENTRATE 10 mg INTRAVENOUS BLA 26 sections